Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cymabay Therapeutics, Inc. (CBAY)  
$32.48 0.00 (0.00%) as of 4:30 Thu 3/21


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 114,780,000
Market Cap: 3.73(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $7.47 - $32.48
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 51,301
Total Buy Value $0 $0 $0 $100,037
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 6,000 242,302 552,511 672,611
Total Sell Value $191,849 $4,799,466 $8,944,114 $10,085,429
Total People Sold 1 5 6 7
Total Sell Transactions 1 15 33 36
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 165
  Page 1 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Dickinson Klara Chief Regulatory Officer   •       –      –    2024-03-22 4 D $0.00 $0 D/D (21,000) 0     -
   Mcwherter Charles President of R&D   •       –      –    2024-03-22 4 D $0.00 $0 D/D (46,938) 0     -
   Shah Sujal Chief Executive Officer   •       •      –    2024-03-22 4 D $0.00 $0 D/D (406,670) 0     -
   Quinlan Paul T General Counsel   •       –      –    2024-03-22 4 D $0.00 $0 D/D (70,262) 0     -
   Emster Kurt Von   –       •      –    2024-03-22 4 D $0.00 $0 D/D (90,000) 0     -
   Shantharam Harish Chief Financial Officer   •       –      –    2024-03-22 4 D $0.00 $0 D/D (20,125) 0     -
   Wills Robert James   –       •      –    2024-03-22 4 D $0.00 $0 D/D (30,000) 0     -
   Shah Sujal Chief Executive Officer   •       •      –    2024-03-13 4 OE $1.06 $655,959 D/D 139,119 406,670     -
   Quinlan Paul T General Counsel   •       –      –    2024-03-13 4 OE $7.89 $329,991 D/D 41,824 70,262     -
   Dorling Janet Director   –       •      –    2024-02-12 4 AS $31.97 $191,849 D/D (6,000) 0 1%     
   Dorling Janet Director   –       •      –    2024-02-12 4 OE $4.63 $27,780 D/D 6,000 6,000     -
   Dickinson Klara Chief Regulatory Officer   •       –      –    2024-01-24 4 A $0.00 $0 D/D 21,000 21,000     -
   Quinlan Paul T General Counsel   •       –      –    2024-01-24 4 A $0.00 $0 D/D 28,438 28,438     -
   Shah Sujal Chief Executive Officer   •       •      –    2024-01-24 4 A $0.00 $0 D/D 96,250 267,551     -
   Mcwherter Charles President of R&D   •       –      –    2024-01-24 4 A $0.00 $0 D/D 31,938 46,938     -
   Shantharam Harish Chief Financial Officer   •       –      –    2024-01-24 4 A $0.00 $0 D/D 20,125 20,125     -
   Mcwherter Charles President of R&D   •       –      –    2024-01-19 4 AS $23.66 $435,645 D/D (18,403) 15,000 33%     
   Mcwherter Charles President of R&D   •       –      –    2024-01-19 4 OE $1.06 $130,522 D/D 18,403 18,125     -
   Quinlan Paul T General Counsel   •       –      –    2024-01-16 4 AS $23.58 $117,898 D/D (5,000) 0 34%     
   Quinlan Paul T General Counsel   •       –      –    2024-01-16 4 OE $2.94 $14,700 D/D 5,000 5,000     -
   Menold Daniel Vice President, Finance   •       –      –    2024-01-16 4 AS $23.58 $235,806 D/D (10,000) 0 34%     
   Menold Daniel Vice President, Finance   •       –      –    2024-01-16 4 OE $4.05 $40,500 D/D 10,000 10,000     -
   Dorling Janet Director   –       •      –    2024-01-10 4 AS $23.86 $143,144 D/D (6,000) 0 39%     
   Dorling Janet Director   –       •      –    2024-01-10 4 OE $4.63 $27,780 D/D 6,000 6,000     -
   Mcwherter Charles President of R&D   •       –      –    2023-12-18 4 AS $21.48 $243,441 D/D (11,332) 15,000 44%     
  165 Records found
  1  2  3  4  5  6  7   
  Page 1 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us